Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.
about
Adhesive Pili in UTI Pathogenesis and Drug DevelopmentUrinary tract infections: epidemiology, mechanisms of infection and treatment optionsNitazoxanide Inhibits Pilus Biogenesis by Interfering with Folding of the Usher Protein in the Outer MembraneP-fimbriae in the presence of anti-PapA antibodies: new insight of antibodies action against pathogensMucosal immunization with iron receptor antigens protects against urinary tract infection.Towards a vaccine against Escherichia coli-associated urinary tract infections.Waging war against uropathogenic Escherichia coli: winning back the urinary tractIdentification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coliAssembly of CS1 pili: the role of specific residues of the major pilin, CooAMolecular characterization of the Escherichia coli asymptomatic bacteriuria strain 83972: the taming of a pathogen.Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli.Chaperone-usher fimbriae of Escherichia coliPreventing urinary tract infection: progress toward an effective Escherichia coli vaccine.Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii.Urinary tract infections: new insights into a common problem.Blocking the 'MIDAS' touch of Enterococcus faecalisIdentification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coliFunctional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract.Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection.Mellowing out: adaptation to commensalism by Escherichia coli asymptomatic bacteriuria strain 83972.Expression and Purification of the Uropathogenic Escherichia coli PapG Protein and its Surface Absorption on Lactobacillus reuteri: Implications for Surface Display System Vaccines.Structure, Function, and Assembly of Adhesive Organelles by Uropathogenic BacteriaExtraintestinal isolates of Escherichia coli: identification and prospects for vaccine development.Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis.Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infectionsEvaluation and management of recurrent urinary tract infections in children: state of the art.The emerging threat of multidrug-resistant Gram-negative bacteria in urology.What is the role of covert infection in detrusor overactivity, and other LUTD? ICI-RS 2013.Prophylactic Efficacy of Hyperimmune Bovine Colostral Antiadhesin Antibodies Against Enterotoxigenic Escherichia coli Diarrhea: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.Regulation of P-fimbrial phase variation frequencies in Escherichia coli CFT073.Immunization with the biologically active lectin domain of PapGII induces strong adhesion-inhibiting antibody responses but not protection against avian pathogenic Escherichia coli.Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.
P2860
Q26752944-14D36720-6DBF-4649-86F9-7E41607046E9Q27022487-D5D9D2DB-74F2-4B75-A02A-E972AA1CC18BQ30277655-DB565D95-F6C9-42CF-A5F9-A5BCAD870C84Q30558351-1D940E42-6BA6-484E-A6C7-F5D8A5AF77E4Q33508792-85D40F40-FCAB-4068-AF92-2456ECF1932FQ33538262-C8CD89D3-052D-4B4A-93FC-00C60397090BQ33613902-267A5933-F1ED-4954-B758-65C3486EEAD4Q33927393-65BDB454-A03C-4648-94C5-92287BE3BEBCQ34233229-B9F6D09D-FFB5-46C1-B386-8FAF3E0D771FQ34301228-D4AB185F-154C-4ADC-8484-764A7F6BCCFDQ34440901-CFF15C66-F634-4723-A09D-2D7C059D449FQ34575131-4B3F1A8A-9C2F-4F95-B26C-FBF01E7FC6FAQ34641267-5C27B478-982B-44D4-ACE8-99B65E0E773DQ35015181-50179E62-0577-4309-AABC-B9B227207AC4Q35521227-77133BCC-F353-49C0-A559-FD4FEC302612Q35625227-5273E9AC-4D75-4316-9803-89F278D5A432Q35783832-E030BA72-DA4C-4745-A930-2820714748A1Q35913583-027D210B-63EF-474F-A95E-992F017605C7Q35949664-44DE6771-6DFC-4687-A7C3-04E3F3B67D13Q35949736-953755F9-F4A9-4FD7-95B7-0D9DC9681C1CQ36171857-63B210AF-C0D9-459D-8F0B-631C504B1DB5Q36263415-C23E43CA-7DA3-440C-9AB1-635D18332AA7Q36383799-65420930-61EC-4460-9B08-61E2D98A8D7BQ36471330-E51F22E3-36FB-4302-AF93-E6C53DAB4270Q36951570-246C0FE1-D693-446A-B650-0B8C19EBEAAFQ37230837-7FED5E8B-8E81-4C02-B50F-3DCE539E0116Q38285468-518D27D1-8FA3-44B3-855D-97934A14D540Q38579512-16D24D5B-644A-4429-B1E1-469F4925B43EQ39189283-E45ADEA8-982E-40F5-A76C-B2130E979B69Q40199741-0F540FBA-C435-4B4D-9B31-9F4A2CDBEB85Q42432445-7CDED699-409B-471B-8B1D-743DC35E2DA9Q51186944-2BF6D95F-0969-40F2-A1A1-08235178BCE9Q54448728-9E6F58AA-EA9D-46A6-A852-281CB5F7F09D
P2860
Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Antibody responses and protect ...... scherichia coli PapDG protein.
@ast
Antibody responses and protect ...... scherichia coli PapDG protein.
@en
type
label
Antibody responses and protect ...... scherichia coli PapDG protein.
@ast
Antibody responses and protect ...... scherichia coli PapDG protein.
@en
prefLabel
Antibody responses and protect ...... scherichia coli PapDG protein.
@ast
Antibody responses and protect ...... scherichia coli PapDG protein.
@en
P2093
P2860
P1476
Antibody responses and protect ...... Escherichia coli PapDG protein
@en
P2093
Gary Baskin
James A Roberts
Jerome S Pinkner
M Bernice Kaack
Scott J Hultgren
P2860
P304
P356
10.1097/01.JU.0000116123.05160.43
P407
P577
2004-04-01T00:00:00Z